Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Santen Set to Thwart Post-Launch Challenges Expected for Myopia Drug Hopefuls: President
May 18, 2023
- Takeda’s cTTP Therapy Gets Priority Review in US
May 18, 2023
- Lecanemab Accepted for Review by Canadian Authorities: Eisai/Biogen
May 18, 2023
- Sony, Astellas Ink Research Deal for ADC Discovery Using Linker Technology
May 17, 2023
- Nonprescription Obesity Med Unlikely to Hit Japan Market Until Next Year
May 17, 2023
- Daiichi Sankyo Set to Sharpen Focus on Innovation with Generic Divestment
May 17, 2023
- Kenzo Sawai to Quit Group Management to Focus on Advocacy
May 16, 2023
- Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
May 16, 2023
- Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge
May 16, 2023
- 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
May 16, 2023
- Eisai’s FY2022 Sales Slip 1.6% on Lower Milestones, Year-Before Gain
May 16, 2023
- FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
May 16, 2023
- Keytruda-Chemo Combo Filed for 1st Line Gastric Cancer in Japan: MSD
May 15, 2023
- Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
May 15, 2023
- Otsuka’s Q1 Pharma Sales Climb 20.3% Buoyed by Global Products
May 15, 2023
- Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
May 12, 2023
- Astellas Loses Appeal Bid in Lexiscan Patent Infringement; Ruling Finalized
May 12, 2023
- Oral Radicava Approved in Switzerland: Mitsubishi Tanabe
May 12, 2023
- Rexulti Snags US Approval for Alzheimer’s Agitation: Otsuka/Lundbeck
May 12, 2023
- Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
May 11, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…